Karen L. Smith's most recent trade in Skye Bioscience Inc was a trade of 75,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 31, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Skye Bioscience Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2026 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Skye Bioscience Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2026 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Context Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 123,500 | 123,500 | - | - | Stock Option (right to buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 25,000 | 102,100 (0%) | 0% | 0 | Common Stock | |
| Skye Bioscience Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Aurinia Pharma Inc | Karen L. Smith | Director | 21 Nov 2024 | 18,641 | 18,641 | - | - | Director Stock Option (right to buy) | ||
| Aurinia Pharma Inc | Karen L. Smith | Director | 21 Nov 2024 | 12,135 | 24,807 (0%) | 0% | 0 | Common Shares | ||
| Aurinia Pharma Inc | Karen L. Smith | Director | 08 Nov 2024 | 17,913 | 17,913 (0%) | 0% | - | Common Stock | ||
| Aurinia Pharma Inc | Karen L. Smith | Director | 08 Nov 2024 | 17,913 | 0 | - | - | Restricted Stock Units | ||
| Aurinia Pharma Inc | Karen L. Smith | Director | 08 Nov 2024 | 5,241 | 12,672 (0%) | 0% | 8.4 | 44,182 | Common Stock | |
| Skye Bioscience Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Context Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2024 | 19,315 | 19,315 | - | - | Stock Option (right to buy) | |
| Skye Bioscience Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2024 | 40,000 | 40,000 | - | - | Director Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 25,000 | 77,100 (0%) | 0% | 0 | Common Stock | |
| Aurinia Pharma Inc | Karen L. Smith | Director | 18 Aug 2023 | 28,959 | 28,959 | - | - | Stock Option (right to buy) | ||
| Aurinia Pharma Inc | Karen L. Smith | Director | 18 Aug 2023 | 17,913 | 17,913 | - | - | Restricted Stock Units | ||
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 27,750 | 27,750 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 13,900 | 52,100 (0%) | 0% | 0 | Common Stock | |
| Quince Therapeutics Inc | Karen L. Smith | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 225,000 | 225,000 | - | - | Employee Stock Option (right to buy) | |
| Talaris Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 14,501 | 14,501 | - | - | Stock Option (Right to Buy) | |
| Quince Therapeutics Inc | Karen L. Smith | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 170,354 | 194,690 (0%) | 0% | 0 | Common Stock | |
| Talaris Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 29,002 | 29,002 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 12,500 | 38,200 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Karen L. Smith | EVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.85 per share. | 07 May 2021 | 305 | 11,888 (0%) | 0% | 60.8 | 18,559 | Common Stock |